TQH2722
What stands out
- Same target as Dupixent
- Binds to IL-4 receptor, the docking point for both the IL-4 and IL-13 signals
- Injection every 2 weeks in trials
Derived from NCT05970432 · NCT05409326 · UniProt P24394 · US label: Dupixent · This is a summary of public records for informational purposes only. It is not medical advice.
History
Earliest recorded event: Jun 8, 2022. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.
- Sep 11, 2025Phase 3 main data collectedTo Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06552520
- Oct 8, 2024Phase 3 trial startedTo Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06552520
- Jun 19, 2023Phase 2 trial started · Status not confirmed by the sponsorA Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT05970432
- Jun 8, 2022Phase 1 trial posted · Status not confirmed by the sponsorA Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects ClinicalTrials.gov NCT05409326